share_log

Head-To-Head Review: Biomea Fusion (NASDAQ:BMEA) Vs. Amylyx Pharmaceuticals (NASDAQ:AMLX)

Head-To-Head Review: Biomea Fusion (NASDAQ:BMEA) Vs. Amylyx Pharmaceuticals (NASDAQ:AMLX)

正面交锋评论：Bioma Fusion（纳斯达克股票代码：BMEA）Vs.Amylyx Pharmicals（纳斯达克股票代码：AMLX）
Defense World ·  2023/02/06 04:23

Amylyx Pharmaceuticals (NASDAQ:AMLX – Get Rating) and Biomea Fusion (NASDAQ:BMEA – Get Rating) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, valuation, earnings, analyst recommendations, profitability and dividends.

Amylyx Pharmicals（纳斯达克股票代码：AMLX — 获取评级）和Bioma Fusion（纳斯达克股票代码：BMEA — 获取评级）都是医疗公司，但哪只股票更好？我们将根据两家企业的机构所有权、风险、估值、收益、分析师建议、盈利能力和股息实力对这两家企业进行比较。

Profitability

盈利能力

This table compares Amylyx Pharmaceuticals and Biomea Fusion's net margins, return on equity and return on assets.

该表比较了Amylyx Pharmicals和Biomea Fusion的净利润率、股本回报率和资产回报率。

Get
获取
Amylyx Pharmaceuticals
Amylyx 制药
alerts:
警报：
Net Margins Return on Equity Return on Assets
Amylyx Pharmaceuticals N/A -172.54% -93.56%
Biomea Fusion N/A -45.62% -42.69%
净利润 股本回报率 资产回报率
Amylyx 制药 不适用 -172.54% -93.56%
生物群聚变 不适用 -45.62% -42.69%

Earnings and Valuation

收益和估值

This table compares Amylyx Pharmaceuticals and Biomea Fusion's top-line revenue, earnings per share and valuation.

该表比较了Amylyx Pharmicals和Biomea Fusion的最高收入、每股收益和估值。

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Amylyx Pharmaceuticals $280,000.00 8,670.59 -$87.93 million N/A N/A
Biomea Fusion N/A N/A -$41.57 million ($2.44) -3.91
总收入 价格/销售比率 净收入 每股收益 市盈率
Amylyx 制药 280,000.00 美元 8,670.59 -8,793 万美元 不适用 不适用
生物群聚变 不适用 不适用 -4157 万美元 (2.44 美元) -3.91
Biomea Fusion has lower revenue, but higher earnings than Amylyx Pharmaceuticals.
Biomea Fusion的收入较低，但收益高于Amylyx Pharmicals。

Institutional & Insider Ownership

机构所有权和内部所有权

70.6% of Amylyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 50.3% of Biomea Fusion shares are owned by institutional investors. 12.7% of Amylyx Pharmaceuticals shares are owned by company insiders. Comparatively, 45.7% of Biomea Fusion shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Amylyx Pharmicals的70.6％股票由机构投资者持有。相比之下，Biomea Fusion的50.3％的股份由机构投资者持有。Amylyx Pharmicals的12.7％的股份由公司内部人士持有。相比之下，Biomea Fusion的45.7％股份由公司内部人士持有。强大的机构所有权表明，对冲基金、大型基金经理和捐赠基金认为，从长远来看，公司的表现将超过市场。

Analyst Ratings

分析师评级

This is a summary of current ratings and target prices for Amylyx Pharmaceuticals and Biomea Fusion, as reported by MarketBeat.

据MarketBeat报道，这是Amylyx Pharmicals和Biomea Fusion当前评级和目标价格的摘要。

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amylyx Pharmaceuticals 0 1 4 0 2.80
Biomea Fusion 0 0 2 0 3.00
卖出评级 保持收视率 买入评级 强劲的买入评级 评分分数
Amylyx 制药 0 1 4 0 2.80
生物群聚变 0 0 2 0 3.00

Amylyx Pharmaceuticals currently has a consensus price target of $48.20, indicating a potential upside of 31.55%. Biomea Fusion has a consensus price target of $25.00, indicating a potential upside of 162.33%. Given Biomea Fusion's stronger consensus rating and higher probable upside, analysts clearly believe Biomea Fusion is more favorable than Amylyx Pharmaceuticals.

Amylyx Pharmicals目前的共识目标价为48.20美元，表明潜在的上涨空间为31.55％。Biomea Fusion的共识目标价为25.00美元，表明潜在的上涨空间为162.33％。鉴于Bioma Fusion的共识评级更高，可能的上行空间也更高，分析师显然认为Biomea Fusion比Amylyx Pharmicals更有利。

Summary

摘要

Biomea Fusion beats Amylyx Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

与两只股票相比，Bioma Fusion在9个因素中的6个因素上击败了Amylyx Pharmicals。

About Amylyx Pharmaceuticals

关于 Amylyx 制药

(Get Rating)

（获取评分）

Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Amylyx Pharmicals, Inc. 是一家临床阶段的生物制药公司，致力于开发针对肌萎缩性侧索硬化症（ALS）和其他神经退行性疾病的各种疗法。该公司的产品线包括 AMX0035，这是一种双重的 UPR-bax 细胞凋亡抑制剂，由苯丁酸钠和牛磺二醇组成，用于治疗肌萎缩性侧索硬化症。它还在开发用于其他神经退行性疾病的 AMX0035。该公司成立于2013年，总部位于马萨诸塞州剑桥。

About Biomea Fusion

关于 Bioma融合

(Get Rating)

（获取评分）

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Biomea Fusion, Inc. 是一家生物制药公司，专注于发现和开发共价小分子药物，用于治疗基因定义癌症和代谢性疾病患者。其主要候选产品是 BMF-219，这是一种口服生物可利用的、强效和选择性的 menin 共价抑制剂，menin 是多种癌症致癌信号的转录调节剂。该公司成立于2017年，总部位于加利福尼亚州雷德伍德城。

Receive News & Ratings for Amylyx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amylyx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

每天接收 Amylyx Pharmicals 的新闻和评级 -在下面输入您的电子邮件地址，通过Marketbeat.com的免费每日电子邮件时事通讯接收Amylyx Pharmicals及相关公司的最新新闻和分析师评级的简明每日摘要。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发